Feasibility of a collaborative pharmacist prescribing model for patients with chronic disease(s) attending Australian general practices: a preliminary study.
Chronic disease
Collaborative pharmacist prescribing model
Drug related problems
General practice
Pharmacist-general practitioner relationship
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
25
05
2022
accepted:
12
09
2022
medline:
1
5
2023
pubmed:
8
11
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
Pharmacists working in general practices provide medication reviews with recommendations to general practitioners (GPs) to optimise medications. We describe a model where the pharmacist is empowered with increased responsibility to implement agreed recommendations through collaborative prescribing. To assess a collaborative pharmacist prescribing model incorporating increased pharmacist responsibility, for patients with chronic diseases in general practice. This was a pre-test-post-test quasi experimental pilot study using a pharmacist embedded in three Australian general practices. A pharmaceutical care plan was developed with patients and their GP to identify drug related problems (DRPs). The pharmacist discussed recommendations to manage DRPs with the GP and implemented recommendations agreed by the GP and patient over the six-month study period. Outcome measures included acceptance and implementation rate of recommendations made by the pharmacist. The pharmacist made 135 recommendations to optimise medicine use of which 126 (93.3%) were accepted by the GP. There were 105 (83.3%) implemented by the end of the study of which the pharmacist implemented 62 (49.3%). Compared to other Australian studies using a general practice pharmacist model, this study suggested increased pharmacist responsibility through collaborative prescribing led to high acceptance and implementation rates of recommendations to manage DRPs.
Sections du résumé
BACKGROUND
BACKGROUND
Pharmacists working in general practices provide medication reviews with recommendations to general practitioners (GPs) to optimise medications. We describe a model where the pharmacist is empowered with increased responsibility to implement agreed recommendations through collaborative prescribing.
AIM
OBJECTIVE
To assess a collaborative pharmacist prescribing model incorporating increased pharmacist responsibility, for patients with chronic diseases in general practice.
METHOD
METHODS
This was a pre-test-post-test quasi experimental pilot study using a pharmacist embedded in three Australian general practices. A pharmaceutical care plan was developed with patients and their GP to identify drug related problems (DRPs). The pharmacist discussed recommendations to manage DRPs with the GP and implemented recommendations agreed by the GP and patient over the six-month study period. Outcome measures included acceptance and implementation rate of recommendations made by the pharmacist.
RESULTS
RESULTS
The pharmacist made 135 recommendations to optimise medicine use of which 126 (93.3%) were accepted by the GP. There were 105 (83.3%) implemented by the end of the study of which the pharmacist implemented 62 (49.3%).
CONCLUSION
CONCLUSIONS
Compared to other Australian studies using a general practice pharmacist model, this study suggested increased pharmacist responsibility through collaborative prescribing led to high acceptance and implementation rates of recommendations to manage DRPs.
Identifiants
pubmed: 36342565
doi: 10.1007/s11096-022-01488-3
pii: 10.1007/s11096-022-01488-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-508Informations de copyright
© 2022. Crown.
Références
Findlay T, Yen L. Inquiry into chronic disease prevention and management in primary health care. Canberra: Australian primary health care institute; 2016 [cited 2022 July 9]. Available from: https://www.aph.gov.au/DocumentStore.ashx?id=0c53f276-a8fb-4905-b5c4-28d1a31f50b7&subId=400324 . Accessed 30 June 2022
McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag Healthc Policy. 2016;9:143–56.
doi: 10.2147/RMHP.S97248
pubmed: 27462182
pmcid: 4939994
Zhou M, Desborough J, Parkinson A, et al. Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. Int J Pharm Pract. 2019;27(6):479–89.
doi: 10.1111/ijpp.12557
pubmed: 31287208
Nissen L. Pharmacist prescribing: what are the next steps? Am J Health Syst Pharm. 2011;68(24):2357–61.
doi: 10.2146/ajhp110216
pubmed: 22135062
Mills T, Patel N, Ryan K. Pharmacist non-medical prescribing in primary care. A systematic review of views, opinions and attitudes. Int J Clin Pract. 2021;75(3):e13827.
doi: 10.1111/ijcp.13827
pubmed: 33169464
Tonna AP, Stewart D, McCaig D. An international overview of some pharmacist prescribing models. J Malta Coll Pharm Pract. 2008;14:20–6.
The pharmacy guild of Australia. Urinary tract infection pharmacy pilot—Queensland [cited 2022 July 10]. Available from: https://www.guild.org.au/guild-branches/qld/professional-services/uti-pharmacy-pilot . Accessed 14 June 2022
The pharmacy guild of Australia. Community pharmacy is reaching full scope [cited 2022 July 10]. Available from: https://pharmacyfullscope.com.au/home/ . Accessed 14 June 2022
Tan EC, Stewart K, Elliott RA, et al. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Social Adm Pharm. 2014;10(4):608–22.
doi: 10.1016/j.sapharm.2013.08.006
pubmed: 24161491
Tan ECK, Stewart K, Elliott RA, et al. Pharmacist consultations in general practice clinics: The Pharmacists in practice study (PIPS). Res Social Adm Pharm. 2014;10(4):623–32.
doi: 10.1016/j.sapharm.2013.08.005
pubmed: 24095088
Freeman C, Cottrell N, Rigby D, et al. The Australian practice pharmacist. J Pharm Pract Res. 2014;44(4):240–8.
doi: 10.1002/jppr.1027
Tan E, Stewart K, Elliott RA, et al. An exploration of the role of pharmacists within general practice clinics: the protocol for the pharmacists in practice study (PIPS). BMC Health Serv Res. 2012;12(1):246.
doi: 10.1186/1472-6963-12-246
pubmed: 22876813
pmcid: 3470952
Freeman C, Rigby D, Aloizos J, et al. The practice pharmacist: a natural fit in the general practice team. Aust Prescr. 2016;39(6):211–4.
doi: 10.18773/austprescr.2016.067
pubmed: 27990049
pmcid: 5155053
Freeman CR, Scott IA, Hemming K, et al. Reducing medical admissions and presentations into hospital through optimising medicines (REMAIN HOME): a stepped wedge, cluster randomised controlled trial. Med J Aust. 2021;214(5):212–7.
doi: 10.5694/mja2.50942
pubmed: 33580553
Peterson GM, Naunton M, Deeks LS, et al. Practice pharmacists and the opportunity to support general practitioners in deprescribing in the older person. J Pharm Pract Res. 2018;48(2):183–5.
doi: 10.1002/jppr.1427
Benson H, Lucas C, Kmet W, et al. Pharmacists in general practice: a focus on drug-related problems. Int J Clin Pharm. 2018;40(3):566–72.
doi: 10.1007/s11096-018-0617-9
pubmed: 29542035
Sudeshika T, Naunton M, Deeks LS, et al. General practice pharmacists in Australia: a systematic review. PLoS ONE. 2021;16(10):e0258674.
doi: 10.1371/journal.pone.0258674
pubmed: 34648595
pmcid: 8516208
Pharmaceutical Society of Australia. Professional Practice Standards—Version 5–June 2017; 2017.
Chew DP, Scott IA, Cullen L, et al. National heart foundation of australia and cardiac society of Australia and New Zealand Australian clinical guidelines for the management of acute coronary syndromes. Heart Lung Circ. 2016;25:895–951.
doi: 10.1016/j.hlc.2016.06.789
pubmed: 27476580
Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults—2016. Med J Aust. 2016;205(2):85–9.
doi: 10.5694/mja16.00526
pubmed: 27456450
The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. Melbourne,: The Royal Australian College of General Practitioners Ltd; 2020. Available from: https://www.racgp.org.au/getattachment/41fee8dc-7f97-4f87-9d90-b7af337af778/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx . Accessed 30 March 2022
Yang I, George J, Jenkins S. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2021. COPD Guidelines Committee. Version 2.63 (February 2021).
Atherton JJ, Sindone A, De Pasquale CG, et al. National heart foundation of Australia and cardiac society of Australia and New Zealand: guidelines for the prevention, detection and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123–208.
doi: 10.1016/j.hlc.2018.06.1042
pubmed: 30077227
Lalor E. National vascular disease prevention alliance In: Guidelines for the management of absolute cardiovascular disease risk. Australia: National Stroke Foundation; 2012. ISBN: 978-0-9872830-1-6
Williams M, Peterson GM, Tenni PC, et al. Drug-related problems detected in Australian community pharmacies: the promise trial. Ann Pharmacother. 2011;45(9):1067–76.
doi: 10.1345/aph.1Q138
pubmed: 21878658
Connor M, Cooper H, McMurray A. The gold coast integrated care model. Int J Integr Care. 2016;16(3):1–8.
Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19(1):118.
doi: 10.1186/s12913-019-3942-3
pubmed: 30760276
pmcid: 6375190
Foubert K, Mehuys E, Maesschalck J, et al. Pharmacist-led medication review in community-dwelling older patients using the GheOP(3) S-tool: general practitioners’ acceptance and implementation of pharmacists’ recommendations. J Eval Clin Pract. 2020;26(3):962–72.
doi: 10.1111/jep.13241
pubmed: 31332905
Kovacevic SV, Miljkovic B, Culafic M, et al. Evaluation of drug-related problems in older polypharmacy primary care patients. J Eval Clin Pract. 2017;23(4):860–5.
doi: 10.1111/jep.12737
pubmed: 28370742
Freeman CR, Cottrell WN, Kyle G, et al. An evaluation of medication review reports across different settings. Int J Clin Pharm. 2013;35(1):5–13.
doi: 10.1007/s11096-012-9701-8
pubmed: 23011269
Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol. 2004;58(6):648–64.
doi: 10.1111/j.1365-2125.2004.02220.x
pubmed: 15563363
pmcid: 1884656
Hazen ACM, Zwart DLM, Poldervaart JM, et al. Non-dispensing pharmacists’ actions and solutions of drug therapy problems among elderly polypharmacy patients in primary care. Fam Pract. 2019;36(5):544–51.
doi: 10.1093/fampra/cmy114
pubmed: 30629165
Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes—randomised controlled trial. Age Ageing. 2006;35(6):586–91.
doi: 10.1093/ageing/afl075
pubmed: 16905764
Wermeille J, Bennie M, Brown I, et al. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team—a pilot study. Pharm World Sci. 2004;26(1):18–25.
doi: 10.1023/B:PHAR.0000013465.24857.a8
pubmed: 15018255
Farrell B, Pottie K, Haydt S, et al. Integrating into family practice: the experiences of pharmacists in Ontario, Canada. Int J Pharm Pract. 2008;16(5):309.
doi: 10.1211/ijpp.16.5.0006
Jorgenson D, Laubscher T, Lyons B, et al. Integrating pharmacists into primary care teams: barriers and facilitators. Int J Pharm Pract. 2014;22(4):292–9.
doi: 10.1111/ijpp.12080
pubmed: 24279947
Zillich AJ, McDonough RP, Carter BL, et al. Influential characteristics of physician/pharmacist collaborative relationships. Ann Pharmacother. 2004;38(5):764–70.
doi: 10.1345/aph.1D419
pubmed: 15031418